主要观点总结
Ascentage Pharma宣布任命Marina S. Bozilenko女士和Debra Yu博士为公司新增的非执行董事，自2024年11月25日起生效。这两位新任董事在全球生物制药行业拥有丰富的财务、投资、商业发展和战略管理经验。文章还介绍了两位新董事的背景和资历，以及Ascentage Pharma的发展情况。
关键观点总结
关键观点1: Ascentage Pharma任命了新的独立非执行董事
Marina S. Bozilenko女士和Debra Yu博士被任命为Ascentage Pharma的独立非执行董事。他们拥有丰富的全球生物制药行业经验和战略洞察力，将帮助公司进入下一个增长阶段。
关键观点2: 新任董事的背景和资历
Bozilenko女士和Yu博士在财务、投资、商业发展和战略管理等方面拥有深厚的经验和专业知识。他们在全球生物制药行业拥有广泛的经验和人脉，对Ascentage Pharma的发展将起到重要的推动作用。
关键观点3: Ascentage Pharma的发展情况
Ascentage Pharma是一家全球性的生物制药公司，致力于发现、开发和商业化疗法，以满足全球未满足的医疗需求。公司的发展处于关键阶段，正在推进全球创新战略，并取得了多项突破性的进展。
文章预览
Ascentage Pharma (6855.HK) today announced that it has appointed Ms. Marina S. Bozilenko and Dr. Debra Yu as additional independent non-executive directors of the company with effect from November 25, 2024. Dr. Dajun Yang Chairman and CEO of Ascentage Pharma I would like to extend a warm welcome to Ms. Marina S. Bozilenko and Dr. Debra Yu, who are joining Ascentage Pharma as independent non-executive directors. Both Ms. Bozilenko and Dr. Yu are accomplished industry veterans possessing a wealth of experience in the finance, investment, business development, and strategic management in the global biopharmaceutical sector. Ascentage Pharma is currently at a crucial stage of its development where we are making further strides with our global innovation strategy. We believe these two distinguished new members of our Board bring with them the invaluable insights and strategic acumen that will help propel the company into its next phase of growth. Ms. Marina S. Bozilenko is currently the Pr
………………………………
